A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01146574
Recruitment Status : Completed
First Posted : June 17, 2010
Last Update Posted : March 8, 2017
Acceleron Pharma, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 7, 2016
  Actual Study Completion Date : March 7, 2016
  Certification/Extension First Submitted : March 7, 2017